New video - Ruxolitinib cream, a first treatment approved in Europe for vitiligo.
Intervention recorded in Paris on June 3, 2023, during the Annual Meetings of Vitiligo
organized by the French Association of Vitiligo.

2 new studies start in the treatment of vitiligo
Study for the treatment of external genitalia.
Study for classically resistant areas (wrist, back of hands, elbows and knees).
More information in the section “Clinical trials in progress" or "Upcoming trials” or by calling 04 92 03 62 25

Last oportunities to participate to the ERASE vitiligo study
patients between 18 to 40 with a vitiligo for last than 6 months.
Please contact Mr Houis Adrien ( houis.a@chu-nice.fr )

After the FDA approval, ruxolitinib cream just received the EMA approval
for treating vitiligo for patients above 12